Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara A Conley

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|April 5, 2017
Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal CancerKelly Y Kim, Quynh-Thu Le, Sue S Yom, et al.
Cancer Informatics|April 11, 2015
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical TrialsYingdong Zhao, Eric C Polley, Ming-Chung Li, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
The Journal of Molecular Diagnostics : JMD|April 24, 2016
Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing AssaysDavid J Sims, Robin D Harrington, Eric C Polley, et al.
Cancer|December 2, 2017
A mutational comparison of adult and adolescent and young adult (AYA) colon cancerJames V Tricoli, Lisa A Boardman, Rajesh Patidar, et al.
International Journal of Radiation Oncology, Biology, Physics|July 12, 2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaCarter Van Waes, Angela A Chang, Peter F Lebowitz, et al.
BMC Medicine|November 16, 2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaborationLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|April 5, 2017
Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal CancerKelly Y Kim, Quynh-Thu Le, Sue S Yom, et al.
Cancer Informatics|April 11, 2015
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical TrialsYingdong Zhao, Eric C Polley, Ming-Chung Li, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
The Journal of Molecular Diagnostics : JMD|April 24, 2016
Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing AssaysDavid J Sims, Robin D Harrington, Eric C Polley, et al.
Cancer|December 2, 2017
A mutational comparison of adult and adolescent and young adult (AYA) colon cancerJames V Tricoli, Lisa A Boardman, Rajesh Patidar, et al.
International Journal of Radiation Oncology, Biology, Physics|July 12, 2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaCarter Van Waes, Angela A Chang, Peter F Lebowitz, et al.
BMC Medicine|November 16, 2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaborationLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Pageof 8